Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YG-02
- Development stage
- Preclinical
- Lead developer
- YGION Biomedical
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
YG-02 is an off-the-shelf, next-generation immunotherapy being developed by YGION Biomedical. It is described as an engineered checkpoint inhibitor and an off-the-shelf cell therapy designed to inhibit immune checkpoint signaling, thereby enhancing antitumor immune responses. Currently in the preclinical stage, the specific immune checkpoint targets and clinical indications for YG-02 have not been publicly disclosed, although its mechanism of action is focused on enhancing the body's natural immune response against tumors.
- Other names
- YG-02 Off-the-shelfYG02 Off-the-shelfYG 02 Off-the-shelfYG-02 (Off-the-shelf)
Beyond the preview
Go deeper on YG-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YG-02.